The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. McKay FC, Gatt PN, Fewings N, Parnell GP, Schibeci SD, Basuki MAI, Powell JE, Goldinger A, Fabis-Pedrini MJ, Kermode AG, et al. Clin Immunol. 2016 Jan 4; 163:96-107. PMID: 26762769. Abstract CommentRecommendBookmarkWatch